Jonathan Schechter and Robert Weinstein Join Oblong's Board of Directors Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new directors to its board. Jonathan Schechter, Partner, The Special Equities Group, and Robert Weinstein, Chief Financial Officer, Synaptogenix, Inc. have joined Oblong's board of directors. In addition, Jim Lusk and Matthew Blumberg have retired from the Oblong board. "We're delighted to welcome Jonathan and Robert to the Oblong board of directors," said Pete Holst, President and CEO. "Both individuals bring a wealth of knowledge in mergers and acquisitions, digital transfor

4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

Delivers Overview of New Strategy for Leveraging AMMO's Existing Assets and Evolving the Company into a Diversified, Growing and Profitable Ecommerce Powerhouse    Highlights Long-Term Opportunity to Achieve $1 Billion in Annual Sales with Strong Cash Flows and Sustainable Margins, Resulting in Superior Value Creation for Shareholders Introduces Diverse Slate with Expertise in Corporate Governance, Ecommerce, Finance, M&A and Strategic Growth Across Relevant B2B and B2C Categories Steven Urvan (together with the other participants in his solicitation, the "Urvan Group" or "we"), who owns approximately 17.1% of the outstanding common shares of AMMO, Inc. (NASDAQ:POWW) ("AMMO" or the "Co

NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announces financial results for the fiscal year ended December 31, 2021. Recent Corporate Highlights: Entered collaboration with Dr. Drew Pinsky to bring awareness to men's health with a focus on driving awareness around erectile and other sexual dysfunctionsPartnered with leading global contract manufacturer to bring production of erectile dysfunction drug STENDRA® to the United StatesLaunched two self-selection studies for erectile dysfunction drug STENDRA®Announced positive over-the-counter (OTC) label compr

S-1 - Petros Pharmaceuticals, Inc. (0001815903) (Filer)

8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)

8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)

8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)

DEFA14A - Petros Pharmaceuticals, Inc. (0001815903) (Filer)

10-Q - Petros Pharmaceuticals, Inc. (0001815903) (Filer)

DEF 14A - Petros Pharmaceuticals, Inc. (0001815903) (Filer)

8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)

8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)

PRE 14A - Petros Pharmaceuticals, Inc. (0001815903) (Filer)

Proprietary technology developing quantum computing and applying AI to better enable Rx to OTC switch candidates across multiple indicationsNEW YORK, NY / ACCESSWIRE / January 7, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announces its conducive position in connection with the recently issued final rule, "Nonprescription Drug Product with an Additional Condition for Nonprescription Use" ("ACNU") by the United States Food and Drug Administration (the "FDA") for companies seeking Rx-to-OTC switch for pharmaceutical products. The Comp

Working to identify quantum computing partnerships to strengthen our AI technology to include critical health records to better enable Rx to OTC switch candidates across multiple indicationsNEW YORK, NY / ACCESSWIRE / December 17, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces a shift in its corporate strategy to focus on the development of its proprietary technology platform as a prospective Rx-to-OTC switch solution across a multitude of conditions and existing Rx only therapies. If this Software as a Service ("SaaS") and S

Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussionsNEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced results of an initial study to determine consumer comprehension of the messaging in its App Technology ("App Comp"), which has unique differences from the current Drug Facts Label ("DFL"). Of the 31 objectives, 29 scored >90% comprehension Point Estimate ("PE"), 30 scored >86.7% comprehension PE, and all scored >80% compreh

NEW YORK, NY / ACCESSWIRE / September 3, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter ("OTC") drug development programs, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 - 11, 2024 at the Lotte New York Palace Hotel.Presentation Date: September 9, 2024Time: Available on-demand starting at 7:00 AM ETInvestors who wish to listen to the Company's presentation can do so by registering for the conference here: https://hcwevents.com/annualco

Utilization of the Company's proprietary Web App showed improved self-selection utilizing an embedded validated diagnostic questionnaire compared to a live interview furthering the Company's efforts to potentially create a first-ever Rx-to-OTC switch in the ED categoryNEW YORK, NY / ACCESSWIRE / July 29, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced results of a subsequent analysis of its pivotal study aimed at facilitating FDA-approved OTC access of the Company's STENDRA® (avanafil) for consumers. This analysis suggested su

Vital study aligned with FDA guidelines shows encouraging performance as Petros continues close FDA contact for a potential technology-centered Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / July 16, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, announces results of the first of a series of pivotal studies aimed at facilitating FDA-approved OTC access of STENDRA® (avanafil) for consumers. The pivotal self-selection study showed that consumers who used the Company's proprietary Web App Technology, designed to assist in the appropriate consumer

Study paves the way toward a first-ever innovation program to include AI-optimization for FDA-guided Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, announces the successful completion of a Formative Human Factors study of its AI-integrated Web App, designed to facilitate OTC access of STENDRA® (avanafil) for consumers. This important development follows the Company's recent execution of an AI licensing agreement with a leading multi-billion dollar software provider announced earlier this y

Team composed of former FDA officials and key clinical and regulatory opinion leaders to help provide insight in preparation for collaboration with FDANEW YORK, NY / ACCESSWIRE / May 21, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces it has formed an Advisory Committee to provide guidance as the company prepares for the potential Rx-to-OTC switch for STENDRA for both development and communication with the U.S. Food and Drug Administration."We believe this diverse team of subject matter experts, which include former FDA officials, will be instrumental in helpin

Lemonaid Health will offer customers more affordable access to branded ED medication STENDRA that may be taken as early as ~15 minutes prior to sexual activity (100mg and 200mg strengths only) [1]Please see Important Safety Information and study design belowNEW YORK, NY / ACCESSWIRE / May 14, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces the availability of all strengths of the Company's prescription erectile dysfunction (ED) medication, STENDRA (avanafil) on the telehealth platform Lemonaid Health, Inc. Lemonaid Health is a subsidiary of 23andMe Holding Co.

SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (NASDAQ:ME), and a leading telemedicine provider, is now offering Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI), prescription erectile dysfunction (ED) medication STENDRAⓇ (avanafil) through its telehealth platform. Working directly with STENDRAⓇ manufacturer Petros Pharmaceuticals, Lemonaid Health is able to offer the fast-acting ED medication at improved pricing. With one in 10 men estimated to have ED at some point in their lifetime1, Lemonaid Health clinicians are able to evaluate and prescribe patients a variety of ED medications at various price points and doses. "We l